1. Home
  2. LTRN vs AKTX Comparison

LTRN vs AKTX Comparison

Compare LTRN & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LTRN
  • AKTX
  • Stock Information
  • Founded
  • LTRN 2013
  • AKTX N/A
  • Country
  • LTRN United States
  • AKTX United States
  • Employees
  • LTRN N/A
  • AKTX N/A
  • Industry
  • LTRN Biotechnology: Pharmaceutical Preparations
  • AKTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LTRN Health Care
  • AKTX Health Care
  • Exchange
  • LTRN Nasdaq
  • AKTX Nasdaq
  • Market Cap
  • LTRN 36.0M
  • AKTX 41.8M
  • IPO Year
  • LTRN 2020
  • AKTX N/A
  • Fundamental
  • Price
  • LTRN $3.37
  • AKTX $1.17
  • Analyst Decision
  • LTRN Strong Buy
  • AKTX
  • Analyst Count
  • LTRN 1
  • AKTX 0
  • Target Price
  • LTRN $25.00
  • AKTX N/A
  • AVG Volume (30 Days)
  • LTRN 51.0K
  • AKTX 27.5K
  • Earning Date
  • LTRN 08-07-2025
  • AKTX 08-18-2025
  • Dividend Yield
  • LTRN N/A
  • AKTX N/A
  • EPS Growth
  • LTRN N/A
  • AKTX N/A
  • EPS
  • LTRN N/A
  • AKTX N/A
  • Revenue
  • LTRN N/A
  • AKTX N/A
  • Revenue This Year
  • LTRN N/A
  • AKTX N/A
  • Revenue Next Year
  • LTRN N/A
  • AKTX N/A
  • P/E Ratio
  • LTRN N/A
  • AKTX N/A
  • Revenue Growth
  • LTRN N/A
  • AKTX N/A
  • 52 Week Low
  • LTRN $2.55
  • AKTX $0.85
  • 52 Week High
  • LTRN $6.12
  • AKTX $4.40
  • Technical
  • Relative Strength Index (RSI)
  • LTRN 50.26
  • AKTX 45.49
  • Support Level
  • LTRN $3.09
  • AKTX $1.10
  • Resistance Level
  • LTRN $3.31
  • AKTX $1.18
  • Average True Range (ATR)
  • LTRN 0.17
  • AKTX 0.07
  • MACD
  • LTRN 0.02
  • AKTX 0.00
  • Stochastic Oscillator
  • LTRN 72.64
  • AKTX 53.25

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: